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Abstract Cell adhesion molecule 1 (CADM1), expressed
by human lung mast cells (HLMCs), mediates their adhe-
sion to airway smooth muscle (ASM), and contributes
to ASM-dependent HLMC proliferation and survival.
CADM1 is expressed in alternatively spliced isoforms, but
those present in HLMCs and their function are not known.
We cloned three functional and one cryptic non-functional
isoform with alternative splicing between exons 7/11 and
1/2, respectively, from HLMCs and human MC lines
(HMC-1 and LAD2). Differentiated HLMCs and LAD2
cells expressed the functional isoform SP4 containing
exons 7/8/11 (*80% of clones), as well as SP1 (exons 7/8/
9/11) and a novel SP6 (exons 7/8/9/10/11). In contrast,
immature HMC-1 cells expressed only functional SP4. SP4
overexpression in HMC-1 cells and HLMCs augmented
homotypic adhesion to a greater extent than SP1 in various
conditions. In contrast, CADM1 downregulation abolished
homotypic adhesion, indicating that CADM1 is the sole
receptor mediating mast cell aggregation. CADM1-medi-
ated adhesion was enhanced by the presence of cell
survival factors. SP1 overexpression in HMC-1 cells
compromised survival compared to SP4 overexpression or
control. CADM1 downregulation resulted in reduced
viability and decreased expression of the pro-survival
protein Mcl-1L, but not Blc-2 or Bcl-XL, and increased
caspase-3/7 activity in both HMC-1 cells and HLMCs. This
coincided with decreased basal Kit levels in HLMCs. In
summary, human MCs express multiple CADM1 isoforms
which exhibit differential regulation of survival and
homotypic adhesion. The most highly expressed SP4 iso-
form is likely to contribute to MC aggregation and
longevity in mastocytosis, and augment the pathophysiol-
ogy of allergic diseases.
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Abbreviations
ASM Airway smooth muscle
CADM1 Cell adhesion molecule 1
HLMCs Human lung mast cells
MCs Mast cells
SP Alternatively spliced isoform
TSLC1 Tumour suppressor of lung cancer 1
Introduction
Mast cells (MCs) play a critical role in the initiation of
inflammation as a primary defence mechanism against
pathogens, but their chronic activation also contributes to
the pathophysiology of numerous diverse diseases includ-
ing autoimmune disorders, allergy and asthma [1]. Human
lung MCs (HLMCs) contribute to both inflammation and
tissue remodelling in lung diseases such as asthma and
pulmonary fibrosis [2], and their relocation within diseased
lung tissue facilitates their interactions with structural cells
Electronic supplementary material The online version of this
article (doi:10.1007/s00018-012-0948-y) contains supplementary
material, which is available to authorized users.
E. P. Moiseeva (&)  P. Bradding
Department of Infection, Immunity and Inflammation,
Institute for Lung Health, Clinical Sciences Wing, Glenfield
Hospital, University of Leicester, Leicester LE3 9QP, UK
e-mail: em9@le.ac.uk
M. L. Leyland
Department of Biochemistry, University of Leicester,
Leicester, UK
Cell. Mol. Life Sci. (2012) 69:2751–2764
DOI 10.1007/s00018-012-0948-y Cellular and Molecular Life Sciences
123
such as airway epithelial cells, fibroblasts and airway
smooth muscle (ASM) cells.
Adhesive interactions between cells are a fundamental
mechanism of cell communication, permitting the accurate
delivery of specific cell–cell signals. In constitutively
adherent cell types, they are also critical for survival by
regulating a specific form of apoptotic death, anoikis [3].
However, MCs, like other cells of haematopoietic origin,
can survive and function in both adherent and suspended
states. Cell adhesion molecule 1 (CADM1) is an immu-
noglobulin superfamily adhesion receptor which mediates
adhesion through either homophilic or heterophilic
molecular interactions. It is expressed on human MCs and
mediates HLMC adhesion to ASM cells in a heterophilic
manner; in turn, this direct contact drives HLMC prolif-
eration and maintains their survival [4, 5]. In mousetg/tg
MCs, heterophilic CADM1-mediated adhesion supports
their survival in the peritoneal cavity and adhesion to
fibroblasts [6, 7]. CADM1 therefore appears to play a key
role in MC biology.
CADM1 is non-redundant in human physiology and has
been implicated in several diseases including cancer, autism
spectrum disorder and venous thrombosis [8–10]. CADM1
expression is significantly reduced in several cancers and
inversely correlated with the disease progression [11–13].
In contrast, CADM1 is upregulated in acute T cell leukae-
mia and contributes to tissue infiltration [14, 15]. Human
CADM1 was originally identified as a tumour suppressor of
lung cancer 1 (TSLC1) [16]. Alternative splicing between
exons 7 and 11 of the CADM1 gene is found in several
species. Bioinformatics analysis of the CADM1 gene and
cDNAs, conducted by the NCBI, Ensembl and by Biederer
[17–19], identified alternatively spliced isoforms (SP) in
several species with common SP4 (TSLC1, containing
exons 7/8/11) and SP3 isoforms (containing exons 7/11),
named here following Biederer [19]. In addition, cDNAs for
human SP2 (with exons 7/9/10/11) and SP1 (exons 7/8/9/
11) are present in DNA databases. Complicating the matter,
CADM1 is a highly glycosylated protein (with a protein
core of *50 kDa) with N-glycosylation mapped to IgG
domains (*25 kDa) and unmapped O-glycosylation
(*25 kDa) [6, 20, 21]. Murine cultured MCs express SP4
and soluble CADM1 (sCADM1 with exon 7/intron 7) [22],
but the isoforms expressed by human MCs and their indi-
vidual roles are unknown.
Final MC differentiation is governed by the local envi-
ronment within the tissue where MCs reside [23], whereas
the majority of studies on MC physiology are conducted
using MCs differentiated in cell culture. In addition, major
phenotypic and functional differences are found between
human and mouse mast cells [24]. The aim of this study
was to characterise CADM1 expression and its role in the
homotypic MC adhesion and survival in differentiated
primary HLMCs and the neoplastic MC lines, HMC-1 and
LAD2 [25, 26], derived from patients with MC leukaemia/
sarcoma. We found that CADM1 is expressed as two major
isoforms, SP4 and SP1, in differentiated human MCs and




The human MC line HMC-1.1 (V560G) was cultured in
Iscove’s Modified Dulbecco’s Medium (IMDM) with 10%
foetal calf serum (FCS) as described previously [27].
HLMCs were isolated from normal lung obtained at sur-
gery for carcinoma by selection using anti-CD117-coated
Dynabeads [27]. The study was approved by the Leices-
tershire Research Ethics Committee and all participants
gave written informed consent. Final MC purity was
[99%. HLMCs were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM), supplemented with 10% FCS,
and 100 ng/ml stem cell factor (SCF), 50 ng/ml IL-6, and
10 ng/ml IL-10 as described previously [5]. Freshly iso-
lated HLMCs were used for cloning and to study CADM1
expression. Stabilised 1- to 2-week-old HLMCs, adapted to
cell culture, were used for adenoviral transduction.
Primary antibodies
Anti-CADM1 3E1 IgY mAb was from Medical and Bio-
logical Laboratories, Japan. Anti-KIT (E1) mAb and anti-
b-actin HRP-conjugated antibody were from Santa Cruz
Biotechnology. Antibodies against KIT (mAb Ab81), Bim
(mAb C34C5), Bcl-2 (mAb 50E3), Bcl-xL (mAb 54H6)
and Mcl-1 (polyclonal #4572) were purchased from New
England Biolabs.
Protein analysis
Surface CADM1 expression was measured using FACS
analysis of non-permeabilised cells. Cells were fixed in 4%
paraformaldehyde in PBS and stained with anti-CADM1
mAb or control IgY, followed by FITC-conjugated anti-
IgY Ab (Fisher Scientific) and then examined using a
FACSCanto with FACSDiva2 software (BD Biosciences,
USA). Since some CADM1 peaks were asymmetric, geo-
metric means were used as a measure of the surface
CADM1. Total protein analysis was conducted as previ-
ously described [28]. SDS-PAGE and immunoblotting
were performed using the NuPAGE electrophoresis system
(Invitrogen, USA). Blots were cut into horizontal strips
with proteins of a close range of molecular weights, probed
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with appropriate antibodies. Alternatively, whole blots
were sequentially probed with antibodies from different
species. Protein bands on exposed films were quantified
using a Syngene image system (Syngene, UK).
Quantification of gene expression
All kits for RNA isolation and cDNA synthesis and Taq-
man probes (CADM1, b-actin, and 18S rRNA) were
purchased from Applied Biosystems, USA. mRNA levels
for CADM1, b-actin, and 18S rRNA were quantified using
MX3000 thermocycler (Stratagene, USA) as previously
described [28]. The relative levels of CADM1 expression
were calculated by the 2-DCT method [29].
Cloning and analysis of CADM1 isoforms
Total RNA was isolated from the cell lines and HLMC
specimens using RNA easy kit (Qiagen, UK). CADM1
cDNA was synthesised using AccuScript RT-PCR kit
(Stratagene, USA) in RT-PCR with nested primers F1–R1
(all oligonucleotide primers are shown in Table 1), followed
by primers F2–R2, and cloned into pSC-B plasmid using a
Strataclone ultra blunt PCR kit (Stratagene, USA). Indi-
vidual clones were isolated for each RNA source and
analysed using several restrictases, including BseR1 and
EcoO1091 with the sites within exons 8 and 10, respectively.
All clones were analysed for alternative splicing between
exons 7/11 and exons 1/2, using PCR with primers exon
7F/exon 11R and exon 1F/exon 2R, respectively. All DNA
sequencing was done by the PNACL at the University of
Leicester (http://www.le.ac.uk/mrctox/pnacl/). Sequences
for CADM1 in bacterial clones p24 (SP4), p33 (SP1), p489
(SP6) and p15 (c15) have accession numbers HE586496,
HE586497, HE586498, and HE586500, respectively, in
EMBL–EBI (http://www.ebi.ac.uk/ena/home).
Modulation of CADM1 expression
SP4 cDNA was re-amplified using oligonucleotides
50CADM1 and CADM1–50GFP, cut with EcoRI and AgeI
restrictases and cloned in frame into EcoRI–AgeI-cleaved
pEGFP-N1 plasmid (Clontech, USA) to express CADM1–
GFP-fusion protein. The fragments for CADM1 cDNAs,
obtained by KpnI–NotI restriction of respective plasmids,
for SP4 (p24), CADM1–GFP (pCADM1-EGFP) and SP1
(p33) were recloned into a vector, provided by BioFocus
(Netherlands, Leiden), and packed in Ad5C20Att01 ade-
novirus by BioFocus. Packaged adenoviruses were then
purchased from BioFocus. All recloned cDNAs were
sequenced to verify correct cloning. CADM1 sh RNAs
(Sh3, Sh4, Sh5) were designed by BioFocus outside areas
of alternative splicing. Luciferase shRNA (LucSh) was
used as a control in downregulation experiments.
Adenoviruses containing SP4–GFP (see Fig. 5b) and
GFP were used to optimise transduction conditions
according to the manufacturer’s recommendations.
Expression of CADM1–GFP or GFP in HMC-1 cells 6 days
post transduction resulted in visible expression at variable
levels in 70 ± 15 and 69 ± 8% of cells, respectively, as
previously reported [30]. Similarly, transduction of various
HLMCs with these viruses for 6 days produced stable and
reproducible fluorescence. Transduction of HMC-1 cells
and HLMCs with a multiplicity of infection of 50 IU/cell
(17 9 3 IU/cell for mixed sh RNAs) for 6 days were used
in all experiments, unless stated otherwise.
Homophilic cell adhesion
Cells, dispersed as a single cell suspension, were cultured in
96-well plates for 3, 18 or 48 h in a cell incubator. Images
were then captured on an Olympus CKX42 microscope
(Olympus, UK). They were viewed and analysed using
Table 1 List of
oligonucleotides
Name Sequence 50?30 Location in the CADM1 gene
F1 ggaggcagccaacgccgcca 50UTR, exon 1
F2 ggacATGGCGAGTGTAGTGCTG Overlapping initiation codon
(ATG), exon 1
Exon 1F CCGAGCGGATCCCAGTGT Exon 1
Exon 2R GTCGCAACCTCTCCCTCGAT Exon 2
Exon 7F CTGGGCCCAACCTGTTCATC Exon 7
Exon 11R AAGCACAGCATGGCGAACAC Exon 11
R1 ggccagttggacacctcattgaa Exon 12, 30UTR
R2 ggctgatCTAGATGAAGTACTCTTT Overlapping stop codon (TAG),
exon 12
50CADM1 ttcgaattcgacATGGCGAGTGTAGTGCTG EcoRI site in 50 to the initiation
codon, exon 1
CADM1–50GFP ctcaccggtgAGATGAAGTACTCTTTCTTTTCTTC AgeI site in 30 to codon 442,
exon 12
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CellF imaging software (Olympus). The aggregates were
outlined on an image and cross-sectional areas of the largest
ten aggregates per photograph of a well were expressed in
pixels2. The size of cell aggregates in every condition was
estimated as the mean of the ten largest aggregates/well in
four wells.
Cell viability
Cell viability was examined by measuring cell number and
caspase-3 activity as described previously [28]. Cell
number was estimated using the ATPlite 1step kit (Perkin-
Elmer, USA) using a calibration curve with a known
number of HMC-1 cells, with luminescence detected in a
plate reader. Caspase-3 activity was measured as accu-
mulation of a specific fluorogenic substrate using the Apo-
one Homogeneous Caspase-3/7 assay (Promega, USA),
detected in a plate reader and expressed in fluorescent
units/cell (FU/cell).
Data analysis
All analysis was performed using GraphPad Prism 5 soft-
ware (GraphPad Software, USA). All data are presented as
the mean ± SE. Differences among the groups were ana-
lysed using a one-way ANOVA, followed by Dunnett’s test
to determine whether the groups were different from a
control group, or Bonferroni’s test to compare multiple
groups. A repeated measures ANOVA was used to compare
multiple data from the same donors. The t test was used to
determine differences between two groups. Pearson’s and
Spearman’s tests were used to analyse correlations.
P \ 0.05 was selected as the level of statistical significance.
Results
CADM1 is highly expressed in HMC-1 cells
Surface CADM1 expression was 4.5-fold higher in the
HMC-1 cells compared to that in HLMCs (Fig. 1a, b). The
total CADM1 protein content, as well as b-actin content,
was also significantly higher in the HMC-1 cells (Fig. 1c).
CADM1 mRNA expression was significantly higher in
HMC-1 cells only when normalised to 18S RNA, but not to
b-actin (ACTB) (Fig. 1d), which is consistent with the
higher b-actin protein levels in HMC-1 cells compared to
HLMCs.
Several CADM1 isoforms are expressed
in human mast cells
First, we obtained full-length cDNA pools by RT-PCR
from the HMC-1 and LAD2 cell lines and two HLMC
specimens, D449 and D450 (donor identification number).
These cDNA pools were cloned and plasmids from indi-
vidual clones were analysed. All data are summarised in
Fig. 2a. Restriction analysis of 109 independent cDNA
clones revealed the presence of alternative splicing
between exons 8 and 11. Sequencing of ten clones con-
firmed this and also identified alternative splicing between
exons 1 and 2 in p15. Next, all plasmids were examined by
PCR for alternative splicing between exons 7/11 and exons
1/2 (not shown). All clones contained exon 8. In addition to
the SP4 isoform (exons 7/8/11), the differentiated LAD2
cells and HLMCs contained *20% of the longer isoform
SP1 (exons 7/8/9/11). A novel SP6 isoform (exons 7/8/9/
10/11) encoded by all 12 exons of the CADM1 gene, which
Fig. 1 CADM1 is highly expressed in HMC-1 cells compared to
HLMCs. Surface CADM1 expression is shown as a plot of geometric
means (a) (n = 3, **P \ 0.01) and a representative histogram for
HMC-1 cells and HLMCs from donors D552–D554 (b). c Western
blot of protein expression in HMC-1 cells and HLMCs from donors
D520, D528 and D529. d Relative CADM1 mRNA levels are shown
as a ratio of CADM1 mRNA molecules to normalisers [103 actin B
(ACTB) mRNA and 106 18S rRNA] (n = 3, ***P \ 0.001)
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has not been described previously in humans or mouse, was
cloned from HLMCs. In contrast, among 25 clones ana-
lysed from undifferentiated HMC-1 cells, 24 clones
expressed the SP4 isoform and 1 clone, p15, contained an
additional 86 nucleotides between exon 1 and 2, denoted as
cryptic exon A in isoform c15 (Fig. 2a). This exon is
located in the middle of the intron 1 and shifts a reading
frame, inducing premature termination of CADM1 trans-
lation (an estimated molecular weight of translated protein
for this and other isoforms is shown in Fig. 2a). The cryptic
exon A is also present in partial CADM1 ESTs BD077366
and DA788329.
In order to investigate functions of individual isoforms,
we used adenoviral delivery of SP4 and SP1, which rep-
resent the majority of CADM1 in differentiated HLMCs.
Significant modulation of CADM1 expression was
achieved by delivery of SP4, SP1 and sh CADM1 RNAs.
Surface expression of SP4 and SP1 was increased up to
206 ± 10 and 148 ± 4%, respectively, compared to con-
trol HMC-1 cells (Fig. 2b). CADM1 Sh5 and mixed Sh
RNAs markedly reduced CADM1 to 41 ± 3 and 25 ± 2%
of control, respectively (Fig. 2b). CADM1 downregulation
with both Sh5 and/or mixed Sh RNAs was used in further
experiments. Western blotting confirmed that modulation
of surface CADM1 was paralleled by changes in total
CADM1 protein in transduced HMC-1 cells (Fig. 2c). SP1
consistently demonstrated a slightly higher molecular
weight compared to SP4 [see Figs. 2c and 5c (below) at
0 h]. Furthermore, SP4–GFP expression influenced
expression and glycosylation of endogenous CADM1
(Fig. 2c). No changes in the total amount of Kit or b-actin
were observed. Similar CADM1 modulation was achieved
in HLMCs [shown in Fig. 6b (below)].
CADM1 mediates homotypic human mast cell adhesion
To examine the role of CADM1 in homotypic mast cell–
cell adhesion, transduced HMC-1 cells were washed and
then cultured for 3 h for analysis of cell aggregation.
HMC-1 cells transduced with SP1, SP4 and control viruses
(GFP and LucSh) formed cell aggregates from single cell
suspension similar to non-transduced cells (not shown),
Fig. 2 Multiple CADM1 isoforms are present in human mast cells.
a The diagram summarises CADM1 isoforms cloned from HLMCs
and cell lines with novel isoforms, SP6 and c15, shown in grey. The
exons present in each clone are depicted not to scale. Alternatively
spliced exons are coloured grey. The percentages of each isoform
present among clones are shown for HLMCs, D449 and D450, and
cell lines, HMC-1 and LAD2. The estimated molecular weight of
each isoform is shown in kDa on the right. The numbers of analysed
clones are shown in italics. For modulation of CADM1 expression,
HMC-1 cells were transduced with adenovirus carrying SP4, SP1,
SP4–GFP or CADM1 sh RNAs (Shm indicates mixed Sh RNAs). Luc
sh RNA and GFP adenoviruses were used as controls. Surface and
total CADM1 protein were detected by FACS (b) (n = 4,
**P \ 0.01, ***P \ 0.001 compared to no virus) or western blotting
(c) (representative of two experiments), respectively
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whereas cells with downregulated CADM1 were present
mostly as single cells (Fig. 3a, top panel). In order to
estimate the sizes of cell aggregates, cross-sectional areas
of the largest aggregates were compared. SP4-over-
expressing cells formed larger aggregates compared to
control HMC-1 cells (Fig. 3b) in agreement with published
data for murine MCs [6]. In contrast, cells with downreg-
ulated CADM1 displayed reduced aggregation compared to
controls (Fig. 3b).
Because SP4 overexpression in HLMCs led to the for-
mation of large aggregates which maintained cell adhesion
in growth medium even after multiple pipetting (Supple-
mental Fig. 1), HLMCs were transduced for a shorter time
(4 days) to examine cell aggregation (Fig. 3a; Supple-
mental Fig. 2). Both SP4- and SP1-transduced HLMCs
formed larger aggregates than control GFP-transduced
HLMCs after 3 h (Fig. 3a, bottom panel). However, SP1
aggregates contained fewer cells than SP4 aggregates and
were not statistically different from control aggregates
(Fig. 3b). Sh5 RNA-transduced cells rarely formed aggre-
gates, whereas control LucSh-transduced HLMCs formed
occasional small aggregates, as did GFP-transduced cells
(Fig. 3a, b). Hence, the SP4 isoform, in contrast to SP1,
promoted fast cell–cell adhesion in both HMC-1 cells and
HLMCs.
Next, we examined cell aggregation over a longer time
period (48 h) and in two culture conditions; normal med-
ium (IMDM ? 10% FCS) and IMDM in the absence of
serum. Both SP4- and SP1-overexpressing HMC-1 cells
formed larger aggregates than control cells after 48 h in
both conditions (Fig. 4a, b). CADM1 downregulation
reduced the size of aggregates only in IMDM ? 10% FCS,
because in the absence of serum non-transduced cells and
cells with downregulated CADM1 did not form aggregates
larger than two to three cells (Fig. 4a, b). In IMDM ? 10%
FCS, cells transduced with all viruses or control cells
formed bigger aggregates compared to those in IMDM
alone (Fig. 4a, b). When the cross-sectional data were
Fig. 3 Modulation of CADM1 expression markedly affects homo-
typic mast cell–cell adhesion. a HMC-1 cells (top panel
representative of two experiments) and HLMCs (bottom panel
representative of one experiment with two pooled samples), were
transduced with adenovirus carrying SP4, SP1 or CADM1 sh RNAs
for 6 and 4 days, respectively. Luc sh RNA and GFP adenoviruses
were used as controls. Transduced cells were resuspended as single
cell suspension and incubated in growth medium for 3 h at 37C.
Original magnification 9100; each experiment was performed in
quadruplicate. The cross-sectional areas of the largest aggregates
were estimated on photographs of four wells for each condition
(b) (n = 40, **P \ 0.01, ***P \ 0.001)
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examined by two-way Anova, both transducing viruses
(P \ 0.0001) and culturing conditions (P \ 0.0001) influ-
enced cell adhesion.
Aggregation of HLMCs was also studied. A diluted
‘‘50% growth medium’’ (50% HLMC medium/50%
IMDM) was used to reduce the potential effect of prolif-
eration. Transduction with either control GFP or LucSh
viruses did not change cell aggregation (Fig. 4c). Non-
transduced or control GFP/LucSh-transduced HLMCs
adhered to plastic and formed small aggregates in ‘‘50%
growth medium’’ after 72 h (Fig. 4c). The portion of
HLMCs, which strongly adhered to plastic and spread on it,
varied in HLMCs from different donors (compare left and
right panels in Fig. 4c). SP4-overexpressing HLMCs
formed larger aggregates compared to control cells in the
same conditions (Fig. 4c) similar to SP4-overexpressing
HMC-1 cells. In contrast, HLMCs with downregulated
CADM1 were present mostly as single round cells and
elongated cells adherent to plastic in ‘‘50% growth med-
ium’’, similar to control, but only as single round cells
in IMDM alone. Paradoxically, CADM1 downregulation in
some HLMCs appeared to reduce adhesion to plastic in
IMDM, suggesting a crosstalk between CADM1 and other
adhesion receptors. Altogether, our data suggested that
CADM1 is responsible for homotypic cell adhesion of
human MCs and CADM1-mediated adhesion is influenced
by survival signalling in both HMC-1 cells and HLMCs.
b2-Integrin and ICAM-1 have been implicated in the
homotypic adhesion of HMC-1 cells and human cultured
MCs [31, 32]. Moreover, MCs express E-cadherin [33, 34],
which may also contribute to aggregation. Hence, we
examined MC aggregation in the presence of EGTA and
Fig. 4 CADM1-mediated adhesion is influenced by CADM1 iso-
forms and survival signalling. a Transduced HMC-1 cells were
cultured for 48 h in IMDM ? 10% FCS (top panel) or in IMDM
alone (bottom panel). Arrows indicate cells with membrane blebbing.
Original magnification 9200; experiments performed in sextuplicate.
The cross-sectional areas of the largest aggregates were estimated on
photographs of four wells for each condition (b) (n = 40, *P \ 0.05,
**P \ 0.01, ***P \ 0.001). c HLMCs transduced with GFP and
LucSh viruses (left panel representative of one donor, each assessed
in quadruplicate) or SP4 and Sh5 adenoviruses (right panel
representative of two donors, each assessed in quadruplicate) for
5 days, washed and grown for 72 h in 50% growth medium (50%
HLMC medium/50% IMDM), or in IMDM alone. Original magni-
fication 9100
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EDTA to inhibit divalent cation-dependent aggregation via
b2-integrins or cadherins. Neither EGTA nor EDTA
affected aggregation of HLMCs cells after 3 h (Supple-
mental Fig. 2 top panel; EDTA data are not shown).
SP4-overexpressing HLMC aggregates were not affected
by incubation in EGTA or EDTA for 3 or 18 h; hence,
neither integrins nor cadherins were involved in HLMC
homotypic adhesion. HLMCs with downregulated CADM1
formed loose aggregates after 18 h only in the absence of
EGTA/EDTA in contrast to non-transduced cells (Supple-
mental Fig. 2). Aggregation of control HMC-1 cells or
cells transduced with SP4 was not affected by either EDTA
or EGTA after 3 or 18 h (Supplemental Fig. 2 bottom
panel). Thus, homophilic CADM1-dependent adhesion is
exclusively responsible for homotypic cell–cell adhesion in
MCs.
SP1 over-expression and CADM1 downregulation
compromise HMC-1 cell viability in the absence
of survival factors
Transduced HMC-1 cells in the absence of serum displayed
membrane blebbing, suggesting that they might become
apoptotic (Fig. 4a). Viability was therefore investigated
further. HMC-1 cells transduced with SP4 or control
Fig. 6 Modulation of CADM1
affects cell viability in HLMCs.
a HLMC survival and caspase-
3/7 activity were measured in
transduced HLMCs after
incubation for 72 h. All were
measured in triplicate for each
donor (n = 3). Survival in
IMDM alone is shown as the
percentage of cells present in
50% growth medium. Caspase
3/7 activity is shown in the
presence (?) or absence (-) of
growth factors. *P \ 0.05,
**P \ 0.01, ***P \ 0.001.
b Pooled HLMCs from donors
(D613 ? D618) and
(D616 ? 619), transduced with
SP4 or Sh5, were analysed by
western blotting (25 lg/lane).
Protein bands in (b) were
quantified, normalised to non-
transduced group and analysed
for correlation (six points for
each protein from two pools
with three groups each) (c).
d Western blot of proteins
(25 lg/lane) from HLMCs
D624, transduced with GFP and
LucSh viruses
Fig. 5 Modulation of CADM1 affects cell viability in HMC-1 cells.
Transduced cells were washed and then incubated in IMDM alone for
48 h. The percentage of viable cells and caspase 3/7 activity (a) were
measured in two experiments each performed in quadruplicate.
Survival is shown as a percentage of cells surviving from the
beginning of the experiment. **P \ 0.01, ***P \ 0.001. b Trans-
duced HMC-1 cells were washed and incubated in IMDM with 1 lM
A23187 for 24 h. Survival and caspase-3/7 activity were measured as
in (a). Two experiments each performed in quadruplicate.
**P \ 0.01, ***P \ 0.001 versus SP4. c Western blot of transduced
cells at 0 and 44 h following removal of viruses in IMDM alone
(representative of two to four experiments for different groups 30 lg/
lane). Abs are shown on the right. d Protein bands, shown in (c) at a
baseline (0 h) were quantified (n = 2). Bands in non-transduced, SP4
and SP1 groups, and non-transduced cells were expressed as
percentages of GFP group; bands in Sh5 and Shm groups were
expressed as percentages of LucSh group. Data for Bcl-2 and Bcl-XL
are not shown. The data with 14 points for each protein (two
experiments with seven groups each) were analysed for correlation.
Regression analysis of these data is shown (e)
b
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viruses survived to a similar degree as non-transduced cells
in IMDM alone (Fig. 5a). In contrast, transduction with
SP1 and Shm viruses decreased survival compared to SP4-
overexpressing cells or control groups (Fig. 5a). These
results indicate that the survival signal is not dependent on
CADM1-dependent homotypic adhesion. The executioner
caspase-3/7 activity was higher in CADM1-downregulated
or SP1-overexpressing cells compared to SP4-over-
expressing or control groups (Fig. 5a). Caspase activity
could not be examined in GFP-expressing cells by this
method. The TUNEL assay confirmed that CADM1
downregulation with mixed Sh RNA resulted in apoptosis
with DNA breaks increased compared to control (not
shown), but this assay was less sensitive than the caspase-3
activation assay. Next, we examined the effect of the cal-
cium ionophore A23187 on the viability of cells with
modulated CADM1. Again, SP4-overexpressing cells
demonstrated better survival and lower caspase-3/7 activity
compared to SP1-overexpressing or CADM1-downregu-
lated cells (Fig. 5b).
Apoptosis-related protein expression was examined in
HMC-1 cells deprived of serum. In particular, we were
interested in Mcl-1 (myeloid cell leukaemia 1) and Bim
(Bcl-2 interacting mediator of cell death) in regard to their
roles in survival of mast cells in vivo and systemic mas-
tocytosis [35–37]. After transduction for 6 days, protein
levels were measured at baseline (0 h) and 44 h later in
IMDM alone (Fig. 5c, d). CADM1 protein expression
increased in control non-transduced, GFP- and LucSh-
transduced cells 44 h after the media change (removal of
serum), representing a possible compensatory response
aimed at maintaining survival. CADM1 increased in Sh5/
Shm-transduced cells due to re-expression of endogenous
CADM1 after removal of transducing viruses (Fig. 5c).
Pro-apoptotic Bim was upregulated at 44 h post removal of
serum and viruses in some cells: particularly in Sh5-
transduced cells, indicating the onset of apoptosis. Anti-
apoptotic Mcl-1 was markedly increased at 44 h post
removal of serum and viruses, and appeared as a strong
doublet band, as described previously [35]; the size of the
shorter Mcl-1 band (C36 kDa) suggested that it was likely
to be phosphorylated rather than alternatively spliced or cut
by caspase-3 [38]. Modifications of Mcl-1 protein affect its
function, such as protein stability and/or interactions with
Bim [38]. Identification of the Mcl-1 shorter band was
beyond scope of this study. Unexpectedly, when protein
levels at the end of the viral transduction period (0 h) were
compared between CADM1 downregulation and controls,
there was a reproducible reduction of Mcl-1 to 68 ± 2 and
57 ± 1% in the Sh5 and Shm groups, respectively
(Fig. 5d). Mcl-1 band densities in combined downregula-
tion (Sh5 ? Shm) were decreased compared to the
combined control (none ? LucSh) group (P \ 0.001,
n = 4). Furthermore, there was a correlation between
CADM1 and Mcl-1 levels in HMC-1 cells with modulated
CADM1 and regression analysis confirmed that CADM1
amounts predicted Mcl-1 levels in HMC-1 cells (Fig. 5d,
e). Thus, several lines of evidence confirm a link between
CADM1 and survival in HMC-1 cells.
CADM1 downregulation compromises HLMC viability
in the absence of survival factors and modulates
expression of Kit and Mcl-1
Next, we studied effect of CADM1 on survival of HLMCs
in similar conditions to those above. HLMC survival in all
conditions was considerably reduced in IMDM alone.
Although SP4 overexpression in HMC-1 cells did not
improve survival compared to controls, SP4-overexpressing
HLMCs survived to a greater extent when compared to
CADM1-downregulated or control cells (Fig. 6a). Incuba-
tion of HLMCs in IMDM alone for 3 days increased
caspase-3/7 activity in SP4- and Sh5-transduced cells, from
3.9 ± 1.0 (50% medium) to 43.9 ± 4.3 FU/cell (IMDM
alone) and 4.5 ± 1.0 (50% medium) to 108.9 ± 19.8 FU/
cell (IMDM), respectively. Caspase-3/7 activity was dras-
tically increased in CADM1-downregulated cells compared
to SP4-overexpressing or non-transduced HLMCs (Fig. 6a).
Hence, high CADM1 SP4 expression due to either high
endogenous expression in HMC-1 cells, or following
overexpression in HLMCs, improves mast cell viability
compared to downregulation in the absence of other sur-
vival factors. These data are in agreement with those
showing a protective effect of ectopic CADM1 expression
on mousetg/tg MC survival in the peritoneal cavity [7].
HLMC specimens were pooled to obtain sufficient
amounts of proteins for analysis. Analysis of two pools
showed different isoforms of Mcl-1 and Bcl-X proteins,
compared to HMC-1 cells, with isoforms indicated in
Fig. 6b as published previously [39, 40]. In addition to the
pro-survival Mcl-1L, HLMCs expressed the pro-apoptotic
Mcl-1ES. Bim levels were very low in HLMCs and detect-
able only in one pool. CADM1 upregulation decreased pro-
apoptotic Mcl-1ES to 24 ± 16% in both pools and decreased
Bim in one pool. CADM1 downregulation resulted in
marked decreases in basal levels of Kit and Mcl-1L to
29 ± 1 and 15 ± 9%, respectively, in both pools. No sig-
nificant changes were observed in HLMCs transduced with
control GFP or LucSh viruses (Fig. 6d). In addition, pro-
apoptotic BimL was detected only in the Sh5-transduced
pool of cells. Protein quantification showed a strong posi-
tive correlation between CADM1 and Mcl-1L levels
(Fig. 6c). Hence, CADM1 modulation induced visible
changes in basal pro-survival/apoptosis protein levels.
Overall, several lines of evidence indicated that CADM1 is
an important survival factor in human MCs.
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Discussion
Much less is known about human CADM1 compared to
mouse CADM1 despite its involvement in several diseases.
For the first time, we have delineated the profile of
CADM1 isoforms in human MCs, and the role of CADM1
in human MC homotypic adhesion and survival. Our data
also revealed a link between CADM1 and Mcl-1, but not
other Bcl-2 family proteins. In contrast to murine MCs
which express only the SP4 and sCADM1 isoforms [6, 22],
human MCs express several functional variants including
SP4, SP1 and SP6, but not soluble CADM1 (not shown). In
addition, we identified novel SP6 and non-functional
cryptic c15 isoforms, which have not been described pre-
viously. Since murine MCs significantly differ from human
MCs in many respects [24], it is possible that CADM1
expression may contribute to some of the observed phe-
notypic differences.
Although the SP4 isoform is prevalent in all human
MCs, the longer SP1 and novel SP6 isoforms were found
only in highly differentiated HLMCs. Interestingly, all
cloned isoforms contained exon 8, encoding 17 Thr codons
out of a total of 28. The NetOGlyc 3.1 server [41] predicts
that the only O-glycosylation sites in CADM1 are all 17
Thr in exon 8 and 4 Thr in exon 9. In agreement with the
data on CADM1 glycosylation, the SP4 protein core is
*50 kDa, but it runs at about 105 kDa in western blots
and is expected to be both N- and O-glycosylated. Con-
sidering that differences between SP4 and SP1 do not
exceed *4–8 kDa (1.1 kDa for amino acid residues
encoded by exon 9 ? four additional O-glycosylation units
with molecular weight about 3.2–6.4 kg/mol [42]), these
isoforms are not easily separated in SDS-PAGE. Similarly,
SP6 is just *1 kDa heavier than SP1. Supporting the
prediction, overexpressed SP1 had a slightly higher
molecular weight compared to SP4 in western blots. The
significance of CADM1 O-glycosylation is not established,
but it is feasible that glycosylated threonines form a stiff
stalk (2.5 A˚ per each glycosylated residue [41]) in the
extracellular domain which moves the first IgG domain,
involved in cell adhesion, further away from cell mem-
brane. This extension might facilitate adhesion, which
could be important for interactions of HLMCs with struc-
tural airway cells.
SP4 and SP1 displayed differences in function in terms
of adhesion and survival. Both isoforms promoted aggre-
gation in some conditions, but SP4 overexpression
promoted fast (within 3 h) cell aggregation of both HLMCs
and HMC-1 cells, whereas SP1 increased aggregation only
after prolonged incubation (48 h). To explain these facts,
we propose the model illustrated in Fig. 7. Since SP1 has a
longer extracellular domain, it is possible that it cannot
align the immunoglobulin domains with those in SP4 and,
as a result, does not form dimers with SP4. Hence, cells
expressing only the SP4 isoform would form CADM1
dimers on the cell surface faster than cells expressing both
SP4 and SP1 with the same CADM1 density on the cell
surface. Since CADM1 dimers are involved in cell adhe-
sion, cells expressing only SP4 would have more functional
CADM1 dimers on the surface and would be able to adhere
faster. However, cells expressing both SP4 and SP1 would
form more SP4/SP4 and SP1/SP1 dimers over a longer
period of time, which would provide strength of adhesion
similar to that in cells expressing SP4 only.
Homotypic adhesion of human MCs is suggested to be
mediated by b2-integrins [31, 32]. In our experiments,
there was little evidence for integrin-dependent homotypic
adhesion. In contrast, downregulation of CADM1 both in
HLMCs and HMC-1 cells markedly reduced homotypic
MC adhesion in normal growth medium and abolished it in
the absence of survival factors. CADM1 is, therefore, a key
receptor mediating homotypic adhesion in both leukaemic
MCs and differentiated HLMCs. The strength of CADM1-
mediated adhesion was influenced by other factors such as
growth conditions and cell type (cells in SP4-transduced
HLMC aggregates did not separate after 6 days, but did in
HMC-1 aggregates), suggesting that cross-signalling plays
a role in CADM1-dependent adhesion. In addition, inter-
actions between CADM1 and Kit may influence adhesion
[5]. A connection between CADM1 and Kit was particu-
larly obvious in HLMCs with downregulated CADM1
(Fig. 6b), where a reduction in CADM1 was paralleled by a
reduction in Kit.
Abnormal accumulation of MC aggregates in various
tissues is characteristic of advanced mastocytosis and MC
accumulation in bone marrow on the background of sys-
temic mastocytosis is a major diagnostic factor for MC
leukaemia [43]. Leukaemic HMC-1 cells express 4.5-fold
more CADM1 than HLMCs, suggesting that CADM1 may
be involved in MC aggregation in this disease. Further-
more, the D816V KIT mutation present in the majority of
patients with mastocytosis is not adequate to induce
aggressive MC disorders in isolation [44]. We propose that
upregulation of CADM1 SP4 may be an important co-
factor. This raises the possibility that MC leukaemia is
analogous to T cell leukaemia with high CADM1 levels
required for malignant transformation and tissue infiltration
[14, 15].
In support of the above hypothesis, the effect of CADM1
on survival was striking both in HLMCs and in HMC-1
cells. SP4 overexpression did not affect survival or caspase-
3/7-activity in HMC-1 cells, but increased survival in
HLMCs, indicating that the relatively high CADM1 SP4
only levels in leukaemic HMC-1 cells are already sufficient
to impart a survival benefit. Conversely, CADM1 down-
regulation reduced survival, increased caspase activity and
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decreased Mcl-1, which is a survival factor for MCs [35, 36]
in both HLMCs and in HMC-1 cells, suggesting a critical
role in MC survival. Thus, reduced viability in cells with
downregulated CADM1 may be caused by reduced
expression of Mcl-1, which would affect the balance
between pro-survival and pro-apoptotic Bcl-2 family pro-
teins impinging on cell viability [45]. The levels of caspase-
3/7 activity upon withdrawal of survival factors in HLMCs
were considerably higher than those in HMC-1 cells, indi-
cating that these leukaemic cells have high anti-apoptotic
signalling. In addition, there were striking differences
between HMC-1 cells and HLMCs in basal levels of pro-
teins involved in cell survival, such as Mcl-1, Bcl-X and
Bim. Moreover, the differences were not only in the levels
of expression, but in the spectrum of expressed isoforms.
In addition, SP1 overexpression reduced HMC-1 sur-
vival, which implies that it may exert dominant-negative
activity over SP4, and may explain why HMC-1 cells only
express functional SP4. Interestingly, leukaemic LAD2
cells, expressing both SP4 and SP1, are less robust, pro-
liferate slowly, and require additional factors for growth
and survival [46]. In the case of SP1, we did not find
specific changes in Mcl-1 expression or any others to
indicate the mechanisms of reduced survival in SP1-over-
expressing MCs. It has been suggested that the presence of
exon 9 in CADM1, which is present in SP1, results in
constitutive shedding of the CADM1 extracellular domain
and an increased presence of the intracellular domain
within cells [47]; this is likely to impact on cell signalling
and may affect CADM1-dependent survival.
Fig. 7 A model of adhesion
mediated by SP4 and SP1.
CADM1 monomers, shown as
grey molecules, are inactive in
adhesion. When cells adhere,
CADM1 forms dimers, shown
as red molecules, which are
actively involved in adhesion.
a Two cells express only SP4,
which forms active dimers
involved in cell adhesion.
b Two cells express both SP4
and SP1 (molecule with
additional protein sequence
encoded by exon 9, shown as a
blue box in SP1 stalk near cell
membrane) with the same
density along cell membrane
(orange line). Because SP4 and
SP1 extracellular domains have
different lengths, they cannot
align properly and form dimers.
The total number of CADM1
dimers, involved in cell
adhesion, is reduced on the cell
surface. However, over time,
most of the CADM1 molecules
would be able to find a matching
partner to dimerise with and
cells would be able to adhere as
strongly as cells expressing only
one CADM1 isoform
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Although the SP4 CADM1 isoform promotes both MC
homotypic adhesion and survival, these two processes do
not appear to be directly related. In the absence of serum,
control non-transduced HMC-1 cells do not aggregate, but
still survive to a similar degree as SP4-transduced cells
which form large aggregates. In contrast, SP1-over-
expressing cells do aggregate but survive to a lesser degree
than control cells, and CADM1 downregulated cells which
do not aggregate have impaired survival. It is therefore
possible to have several scenarios: increased SP1-depen-
dent adhesion with reduced survival, maximal adhesion in
SP4-overexpressing cells with maximal survival, medium
strength adhesion with maximal survival in constitutive
SP4-expressing HMC-1 cells, and minimal adhesion in
CADM1-downregulated cells with reduced survival. This
suggests that CADM1 SP4 and SP1 deliver survival sig-
nalling independently of their role in cell aggregation and
that CADM1-dependent MC survival does not appear to be
dependent on CADM1-dependent adhesion. In this respect,
CADM1 is similar to other immunoglobulin-like CAMs
(cell adhesion molecules), such as NCAM, which can
activate signal transduction cascades in the absence of cell
adhesion [48].
Our data show that CADM1 plays a key role in MC
aggregation and survival and, therefore, is likely to con-
tribute to both clonal expansion and aggregation of MCs in
advanced mastocytosis. Our data indicate that SP4 is a sur-
vival factor for MCs, and it is therefore likely to be of
particular importance for MC survival when other survival
signals are unavailable. HLMCs, as a first line for immune
defence against infections and pathogens, are characterised
by a fast response to the changing environment and reloca-
tion into different lung compartments in disease [2]. CADM1
may provide anti-apoptotic signalling during these physio-
logical changes, which involve disassembly of survival
signalling during cell migration and relocation. CADM1
may also contribute to the longevity of MCs and, thereby,
augment pathology of disorders such as asthma and allergy.
CADM1 is an attractive target for the modulation
of MC-dependent disease. Targeting CADM1-dependent
adhesion directly may not be a useful therapeutic approach
because of its importance in other cell types, but CADM1-
induced signalling is likely to be specific to MCs and a
more appropriate target for intervention. For example, the
CADM1 partners, TIAM in acute T cell leukaemia [49] or
PTPN13 in epithelial cells [50], are not expressed in MCs.
Also, no link between CADM1 and Mcl-1 has so far been
reported. The molecular mechanisms of the CADM1-
mediated pro-survival pathway are not known, but by
delineating isoform-specific expression and intracellular
signalling within different cell types, there is the potential
to modulate cell and tissue-specific CADM1-dependent
processes favourably.
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